findmyKOL
Clinical trialNCT07594145Not, yet, recruitingPhase 2Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

SponsorOregon Health and Science UniversityEnrollment57Cardio-renal Vascular Function and FailureDiabetic Chronic Kidney DiseaseT1D Heart FailureType 1 Diabetes
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Michigan

    Ann Arbor, Michigan, United States

    Lynn Ang, MDMatthias Kretzler, MD
  • Oregon Health & Science University

    Portland, Oregon, United States

    Brian Davidson, MDDavid Ellison, MDJonathan Purnell, MDKristin Childress, MD, MPHRodica Busui, MD, PhD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Finerenone →Sotagliflozin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Nov 2026
Primary completion
31 Dec 2029
Completion
31 Dec 2031
Last update posted
10 Aug 2026
Registered enrollment
57
Registry id
NCT07594145
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.